Skip to main content

CORRECTION article

Front. Immunol., 26 October 2023
Sec. Vaccines and Molecular Therapeutics
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1324894

Corrigendum: Peptide-based vaccine for cancer therapies

Luigi BuonaguroLuigi BuonaguroMaria Tagliamonte*Maria Tagliamonte*
  • Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - “Fond G. Pascale”, Naples, Italy

A corrigendum on
Peptide-based vaccine for cancer therapies

by Buonaguro L and Tagliamonte M (2023) Front. Immunol. 14:1210044. doi: 10.3389/fimmu.2023.1210044

In the published article, there was no Funding statement. The correct Funding statement appears below.

FUNDING

The study was funded by the Italian Ministry of Health through Institutional “Ricerca Corrente” (LB and MT) L2/3 project to LB “Tumor antigen discovery for innovative cancer immunotherapies in HCC: from benchside to bedside (HepAnt)”. L2/13 project to MT “Peptide optimization to improve antigen presentation and anti-tumor response for sarcomas”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: peptides, TAA, TME, molecular mimicry, immunopeptidome, combinatorial strategies, adjuvant, MHC

Citation: Buonaguro L and Tagliamonte M (2023) Corrigendum: Peptide-based vaccine for cancer therapies. Front. Immunol. 14:1324894. doi: 10.3389/fimmu.2023.1324894

Received: 20 October 2023; Accepted: 23 October 2023;
Published: 26 October 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Buonaguro and Tagliamonte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Maria Tagliamonte, m.tagliamonte@istitutotumori.na.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.